On February 9, 2021 Kuraray Co., Ltd. reported it has made the following revisions to the forecast of financial results for the fiscal year ended December 31, 2020 (January 1, 2020 through December 31, 2020) which was announced on December 23, 2020 (Press release, Kuraray, FEB 9, 2021, https://pdf.irpocket.com/C3405/HTFv/ZRb6/LmzE.pdf [SID1234574772]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Revisions to consolidated earnings forecast for the fiscal 2020 (January 1-December 31, 2020)

2. Reason for the revisions For the full fiscal year, net sales and all the earnings accounts following operating income should exceed the previous forecast due to a recovery in demand in automotive, display, and electronic and electrical device applications, and a higher volume than initially expected in the Vinyl acetate and Isoprene segments.